April 16th 2025, 4:00pm
Bria-IMT plus check point inhibitors had a median overall survival which outperformed that of antibody-drug conjugates in HR+ metastatic breast cancer.
April 16th 2025, 3:05pm
Treatment with bexmarilimab and Vidaza elicited high overall response rates in both frontline and relapsed/refractory higher-risk myelodysplastic syndrome.
April 16th 2025, 1:00pm
Dr. Nataliya Uboha sat down to discuss the early warning signs of esophageal cancer, as well as important key takeaways for those with the disease.
April 15th 2025, 9:00pm
Erleada reduced the risk of death by more than 20% compared with other treatments in metastatic castration-sensitive prostate cancer.
April 15th 2025, 7:00pm
Subcutaneous Opdivo showed comparable effectiveness, safety and tolerability to IV Opdivo in advanced clear cell renal cell carcinoma.
April 15th 2025, 5:00pm
What is lovely never dies, but passes into other loveliness, Stardust or seafoam, flower or winged air. ― Thomas Bailey Aldrich
April 15th 2025, 4:00pm
Pheast Therapeutics has treated the first patient in a phase 1 trial of PHST001, a novel macrophage checkpoint inhibitor for advanced solid tumors.
April 15th 2025, 3:00pm
A phase 2a clinical trial of NEO100-01 is continuing to recruit patients with malignant gliomas, with full enrollment expected in September.
April 15th 2025, 1:00pm
Nubeqa plus hormone therapy improved outcomes in metastatic prostate cancer, reducing disease progression and showing a favorable safety profile.
April 14th 2025, 9:00pm
Tara Sweeney, BSN, RN, OCN, CHPN discussed best care for the health and well-being of a person across all stages of their cancer survivorship.
When a Thoughtless Mammogram Reminder Reopened a Deep Cancer Wound
A Lifelong Advocate and Innovator
Personalized Breast Cancer Care for Older Adults Goes Beyond Age
Unmatched Energy, Every Single Day